Transaction details
On March 12, 2026, Stephen Mayo, a director at Sarepta Therapeutics (NASDAQ: SRPT), sold 7,239 shares of the company's common stock at $17.02 per share. The sale generated proceeds of $123,207. After completing that trade, Mayo directly holds 1,765 shares of Sarepta stock.
Reason for the sale
The company reported that the disposition was executed to cover tax liabilities incurred when restricted stock units vested. The filing identifies the tax payment as the purpose of the sale rather than an investment decision or disposition for other reasons.
Share-price context
At the time the stock was trading near $16.40, representing an 84% decline from its 52-week high of $103.32. The filing does not link the insider sale to any view on valuation; it reports the sale as a tax-driven transaction tied to RSU vesting.
Analyst and company developments
Brokerage coverage and company communications have continued alongside the insider transaction. Mizuho raised its price target on Sarepta to $31 and kept an Outperform rating, citing revised expectations for product sales and operating expenses. Jefferies maintained a Buy rating with a $30 price target after presentations at the Muscular Dystrophy Association conference, and the firm noted the potential for FDA discussions in March 2026 related to full approvals for Amondys and Vyondys. Freedom Capital Markets increased its price target to $25 while staying at Buy, and flagged that product revenue had declined following a weakened reputation for ELEVIDYS in 2025.
Jefferies analyst Andrew Tsai described Sarepta as a possible recovery candidate and pointed to a new Elevidys launch initiative that could boost sales in the back half of 2026. Separately, Sarepta is scheduled to present clinical data at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference. The company will deliver a late-breaking presentation on delandistrogene moxeparvovec gene therapy that includes Phase 3 EMBARK results up to three years post-infusion and caregiver-reported impressions from two years of follow-up.
Valuation commentary
Analysis from InvestingPro included with the filing indicates that the stock appears undervalued at current levels and references a Pro Research Report covering SRPT among more than 1,400 U.S. equities, available to subscribers. The report itself is not reproduced in the filing; the note merely points readers to that resource for deeper analysis.
What this means
The director sale was disclosed as a tax-related action following RSU vesting and left Mayo with a modest direct holding. At the same time, analysts have adjusted their models and price targets and the company is preparing to share extended follow-up trial data that market participants may view as relevant to future approvals and product uptake.